Shaily Engineering Plastics (501423) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue grew 38% year-over-year to INR 246.7 crores, driven by a 181% surge in healthcare segment revenue and capacity expansion initiatives.

• EBITDA margin expanded by 840 basis points to 28.5%, with EBITDA at INR 70.4 crores, and PAT up 146% year-over-year to INR 41.1 crores.

• Significant operational expansion with new injection molding machines and contracts in healthcare and consumer segments.

• Unaudited standalone and consolidated financial results for Q1 FY26 were reviewed and approved by the Board on August 11, 2025.

• Statutory auditors conducted a limited review and found no material misstatements in the financial disclosures.

Financial highlights

• Q1 FY26 consolidated revenue: INR 246.7 crores (+38% YoY); standalone revenue: INR 225.1 crores (+33% YoY).

• EBITDA: INR 70.4 crores (95% growth); EBITDA margin at 28.5%.

• PAT: INR 41.1 crores (146% growth); PAT margin at 16.7%.

• Cash PAT: INR 52.6 crores (91% growth).

• Gross profit margin improved by 910 bps YoY to 42.1% (consolidated).

Outlook and guidance

• Healthcare business expected to drive significant revenue and profitability growth over the next few years.

• Capacity expansion in healthcare to reach 70–75 million pens by early FY27, with 50–60 million backed by customer commitments.

• 19 new injection molding machines being installed to meet healthcare demand, completion expected by Q2 FY26.

• Commercial manufacturing of GLP-1 pens for semaglutide has commenced; further expansion planned for additional variants.

• Consumer and mixed-materials business seen as scalable with strong growth potential.